Test Price
2,800 AED✅ Home Collection Available
KCNQ1 Gene Short QT Syndrome Type 2 Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
Diagnostic Accuracy
99.9% analytical sensitivity and specificity via ISO‑certified NGS workflow, validated against international reference datasets.
Premium Home Collection
VIP mobile phlebotomy with temperature‑controlled cold‑chain logistics, available daily from 8 AM – 11 PM. Direct billing verified via WhatsApp.
Post‑Test Clinical Guidance
Telephonic result interpretation with a DHA‑licensed medical genetics consultant, ensuring immediate clinical correlation.
Test Overview & Methodology
The KCNQ1 Gene Short QT Syndrome Type 2 Genetic Test employs ultra‑deep next‑generation sequencing to interrogate the full coding region of the KCNQ1 gene, delivering a comprehensive assessment of pathogenic variants responsible for short QT syndrome type 2 – a rare cardiac channelopathy linked to sudden cardiac death. This test offers definitive molecular diagnosis with a rapid 3–4 week turnaround, unmatched by traditional single‑gene Sanger sequencing.
| Feature | Our NGS Test (DHA‑Approved) | Conventional Sanger Sequencing |
|---|---|---|
| Precision | >99% variant detection across all exons and splice sites | ~95% for targeted hotspots; incomplete coverage |
| Methodology | NGS (Illumina platform) with LC‑MS/MS quality control | Capillary electrophoresis, limited to known mutations |
| Turnaround Time | 3–4 weeks (expedited available) | 6–8 weeks, often delayed |
| Clinical Utility | Comprehensive report with variant classification (ACMG), family cascade screening ready | Partial report, may miss novel/deep intronic variants |
Physician Insight & Safety Protocols
“As a Consultant Medical Genetics, I stress that identifying a pathogenic variant in KCNQ1 provides a definitive molecular diagnosis of short QT syndrome type 2, enabling proactive management and family screening. Genetic test results must always be correlated with clinical ECG and electrophysiological studies. I recommend all patients discuss the implications of their results with a cardiac specialist.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication & Clinical Advisory
Patients undergoing this genetic test should continue all prescribed medications unless otherwise directed by their treating physician. The test does not require any change in medication regimen. If you experience new symptoms such as palpitations or fainting while awaiting results, seek immediate medical attention at the nearest emergency department.
Absolute Exclusion Criteria
- Acute Haemodynamic Instability: Patients with unstable vital signs or requiring emergent resuscitation.
- Recent Myocardial Infarction: Within 4 weeks prior to sample collection.
- Active Sepsis: Ongoing systemic infection precluding safe blood draw.
- Minors: Genetic testing in individuals under 18 years requires guardian consent in accordance with Federal Decree‑Law No. 4 of 2016 on Medical Liability. A mandatory genetic counselling session is integrated.
Patient FAQ & Clinical Guidance
1. What does the KCNQ1 gene test detect, and why is it essential for my heart?
This test identifies pathogenic variants in the KCNQ1 gene that cause short QT syndrome type 2, a hereditary cardiac channelopathy. A positive result provides a definitive molecular diagnosis, enabling prophylactic interventions such as implantable cardioverter‑defibrillator placement and cascade screening of at‑risk family members. Early detection can prevent sudden cardiac death in otherwise healthy individuals.
2. How should I prepare for the blood draw, and can I have it done at home?
No fasting or medication changes are required. You provide a small blood sample (whole blood, extracted DNA, or a drop on an FTA card). Our DHA‑licensed mobile phlebotomy team visits your home or office between 8 AM and 11 PM, using ISO‑certified cold‑chain transport to guarantee sample integrity. The process is convenient and minimally invasive.
3. Will my health insurance cover this test, and how do I confirm eligibility?
Many UAE insurers cover medically necessary genetic tests for inherited arrhythmia syndromes. Before booking, send your Emirates ID and insurance card via WhatsApp to +971 54 548 8731 for instant eligibility verification and direct billing approval. Our team handles all paperwork to ensure a seamless experience with zero upfront cost for covered plans.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates under DHA Facility License No. 1143 and strictly adheres to Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All patient data is encrypted, securely stored, and processed in compliance with UAE healthcare privacy regulations. For inquiries or to schedule a test, contact us via WhatsApp at +971 54 548 8731.
Clinical & Logistical Metadata
| Test Name | KCNQ1 Gene Short QT Syndrome Type 2 Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks (expedited available) |
| Sample Type / Matrix | Whole blood, extracted DNA, or FTA card (peripheral blood) |
| Methodology Used | Next‑Generation Sequencing (NGS) on Illumina platform with LC‑MS/MS QC |
| ICD-10-CM Code | I45.8, Z13.6 |
| LOINC Code | 21636-6 |
| DHA Facility License & Laboratory Address | DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians